457-97-6 Usage
Uses
Used in Pharmaceutical Industry:
3-[(4-Fluorobenzyl)oxy]benzoic acid is used as a building block for the synthesis of various drugs and pharmaceutical intermediates. Its unique structure enables the development of new pharmaceuticals with enhanced efficacy and reduced side effects.
Used in Drug Discovery and Development:
3-[(4-Fluorobenzyl)oxy]benzoic acid serves as a precursor for the synthesis of various pharmacologically active compounds. Its potential applications in drug discovery and development make it a valuable asset in the creation of innovative and effective medications.
Check Digit Verification of cas no
The CAS Registry Mumber 457-97-6 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 4,5 and 7 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 457-97:
(5*4)+(4*5)+(3*7)+(2*9)+(1*7)=86
86 % 10 = 6
So 457-97-6 is a valid CAS Registry Number.
InChI:InChI=1/C14H11FO3/c15-12-6-4-10(5-7-12)9-18-13-3-1-2-11(8-13)14(16)17/h1-8H,9H2,(H,16,17)
457-97-6Relevant academic research and scientific papers
Hydrophobicity-oriented drug design (HODD) of new human 4-hydroxyphenylpyruvate dioxygenase inhibitors
Ndikuryayo, Ferdinand,Kang, Wei-Ming,Wu, Feng-Xu,Yang, Wen-Chao,Yang, Guang-Fu
, p. 22 - 31 (2019/01/26)
Involved in the tyrosine degradation pathway, 4-hydroxyphenylpyruvate dioxygenase (HPPD) is an important target for treating type I tyrosinemia. To discover novel HPPD inhibitors, we proposed a hydrophobicity-oriented drug design (HODD) strategy based on the interactions between HPPD and the commercial drug NTBC. Most of the new compounds showed improved activity, compound d23 being the most active candidate (IC50 = 0.047 μM) with about 2-fold more potent than NTBC (IC50 = 0.085 μM). Therefore, compound d23 is a potential drug candidate to treat type I tyrosinemia.
